Effects of DDAVP on haemostasis of a patient with vWD type 2B
| Time after DDAVP | Bleeding time (min) | F VIII:C (%) | vWF:Ag (%) | RiCoF (%) | Platelet count (× 109/l) |
|---|---|---|---|---|---|
| 0 min | >30 | 80 | 54 | 14 | 85 |
| 30 min | nd | 190 | 79 | 70–112 | 40 |
| 60 min | 9 | 165 | 90 | nd | 64 |
| 120 min | 6 | 150 | >100 | nd | 44 |
| 240 min | >30 | 94 | 87 | nd | 49 |
| 24 hours | >30 | 61 | 56 | nd | 70 |
DDAVP (0.3 μg/kg body weight) was administered as a 30 minute infusion. Subsequently, bleeding time, vWF:Ag, F VIII:C, ristocetin cofactor (RiCoF), and platelet counts were determined 30, 60, 120, 240 minutes and 24 hours after infusion in the patient firstly reported.
nd=not done.